Neuroplast
neuroplast.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$10.8M
3 rounds on record
Latest round
$10.8M
Series B · Nov 2021 · 4 yr ago
Grants
$84k
2 grants · CORDIS
Backers
1
LIOF
The money's age
Long since its last round
58 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 1, 2023
Won a grant $40k · CORDIS
Nov 17, 2021
Raised a round Series B $10.8M · PRNewswire
Mar 1, 2021
Won a grant $45k · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jan 2023 | $40k | — | CORDIS |
| Series B | Nov 2021 | $10.8M | Lumana Invest, Brightlands | PRNewswire |
| Grant | Mar 2021 | $45k | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
LIOF Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Lamina's Tech: A Game-Changer in Regenerative Medicine. Spin-off from INSERM - University of Strasbourg UMR1260 Regenerative Nanomedicine…
セレイドセラピューティクス - 細胞治療(造血幹細胞). Change the futurewith cell therapy.
Unlocking new possibilities for millions with neurological disease.
Syntax Bio is a synthetic biology company programming the next generation of stem cell-derived therapies and organoids.
Targeting cells to treat disease. 1030 Brittan Ave, San Carlos, CA 94070.
ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries.
News
Spinal Cord Injury Market Size, Emerging Therapies, and Forecast Insights Through 2036 - DelveInsight Nipro Corp, Kringle Pharma, Abbvie, Neuroplast, Kringle Pharma ...
Read more
Report
Neuroplast successfully completes patient inclusion of Phase II clinical trial for Traumatic Spinal Cord Injury
Read more
Report
Neuroplast receives second orphan medicinal product designation for Neuro-Cells, paving the way for application to both chronic and trauma-induced neurodegenerative diseases
Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury An orphan medicinal product...
Read more
Report
GENFIT S.A.: GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapiesNTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical
Read more
Report
Stem cell biotech Neuroplast enrolls first patient in Phase II clinical trial of transformative Neuro-Cells treatment for Traumatic Spinal Cord Injury
Read more
Report
Dutch stem cell biotech Neuroplast secures € 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy for Traumatic Spinal Cord Injury
- € 10 million (US$ 11.5 million) raised to obtain conditional EMA market approval for treatment of Traumatic Spinal Cord Injury - Clinical Phase I trial...
Read more
Report
Dutch stem cell biotech Neuroplast secures € 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy for Traumatic Spinal Cord Injury
/PRNewswire/ -- Dutch clinical phase biotech Neuroplast raised a total of € 10 million (US$ 11.5 million) in funding from investors Lumana Invest, Brightlands...
Read more
Report
Neuroplast announces positive results from phase I trial with Neuro-Cells stem cell treatment for traumatic spinal cord injury
Neuroplast announces positive results from phase I trial with Neuro-Cells stem cell treatment for traumatic spinal cord injury
Read more
Report
Show more news